RIGL Financial Facts
Total costs and expenses: 25.71MIncome (loss) from operations: -25.71M
See Full Income Statement
Total current assets: 275.41M
Other long-term liabilities: 91K
See Full Balance Sheet
Earnings History for Rigel Pharmaceuticals, Inc. (RIGL)
|
Expand Research on RIGL
| Next EPS Date | 8/6/13 *Est. | EPS Growth Rate | +9.4% *Last Qtr. |
|---|---|---|---|
| Average EPS % Beat Rate | +0.7% | Revenue Growth Rate | -100.0% *Last Qtr. |
| Average % Move 1-Wk after EPS | -2.2% |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Estimize EPS/Revs | Gd. | % Since | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 3/1/11 | Q410 | -$0.33 | -$0.36 | +$0.03 | N/A | $4.82M | N/A / N/A | N/A | -44.9% | Details | |
| 3/5/12 | Q411 | -$0.36 | -$0.28 | -$0.08 | N/A | $2.23M | N/A / N/A | N/A | -60.4% | Details | |
| 5/7/13 | Q113 | -$0.29 | -$0.30 | +$0.01 | N/A | $1.73M | N/A / N/A | N/A | -18.1% | Details | |
11/6/12  |
Q312 | -$0.36 | -$0.37 | +$0.01 | N/A | $750K | N/A / N/A | N/A | -55.3% | Details | |
| 5/3/11 | Q111 | -$0.40 | -$0.36 | -$0.04 | N/A | $630K | N/A / N/A | N/A | -57.7% | Details | |
| 5/1/12 |
Q112 | -$0.32 | -$0.31 | -$0.01 | $750K | $620K | N/A / N/A | N/A | -50.2% | Details | |
| 8/7/12 |
Q212 | -$0.35 | -$0.35 | $0.00 | $1.15M | $550K | N/A / N/A | N/A | -64.3% | Details | |
| 8/2/11 | Q211 | -$0.37 | -$0.38 | +$0.01 | $395K | $420K | N/A / N/A | N/A | -54.9% | Details |
